NAMS
NewAmsterdam Pharma Co N.V.Company Information
- Company Name
- NewAmsterdam Pharma Co N.V.
- CIK
- CIK0001936258
- Category
- Large accelerated filer
- Ticker: Exchange
- NAMS: Nasdaq, NAMSW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NAMS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-14
- Last sale
- 2026-09-04
- Shares purchased (TTM)
- 10,660
- Shares sold (TTM)
- 1,359,349
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 116,125,544
- Shares outstanding
- 123,370,232
- Ownership
- 94.13%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -5.54%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
| Cash | - | - | - | - | - | - | - | 423 | 431 | 481 | 340 | ||||||
| Cash And Cash Equivalents At Carrying Value | 424 | 458 | 490 | 538 | 564 | 748 | 772 | 423 | - | - | 340 | ||||||
Assets Current | |||||||||||||||||
| Assets Current | 659 | 658 | 676 | 732 | 770 | 817 | 863 | 438 | 445 | 488 | 347 | ||||||
| Prepaid Expense And Other Assets Current | 24 | 21 | 38 | 28 | 31 | 9 | 24 | 15 | 15 | 7 | 6 | ||||||
| Marketable Securities Current | 210 | 178 | 146 | 165 | 175 | 60 | 62 | - | - | - | - | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Marketable Securities Noncurrent | 44 | 71 | 93 | 53 | 44 | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Intangible Assets Net Including Goodwill | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Prepaid Expense Noncurrent | - | 3 | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Assets | 704 | 733 | 769 | 786 | 815 | 818 | 865 | 439 | 447 | 488 | 347 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||
| Accounts Payable Current | 5 | 8 | 9 | 4 | 6 | 6 | 5 | 7 | 5 | 9 | 17 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 10 | 5 | 15 | 10 | 9 | 8 | 14 | 11 | 10 | 10 | 11 | ||||||
Liabilities Current | |||||||||||||||||
| Deferred Revenue Current | 3 | 4 | 4 | - | - | 3 | 6 | 4 | 6 | 8 | 9 | ||||||
| Liabilities Current | 73 | 67 | 86 | 58 | 37 | 41 | 107 | 41 | 45 | 60 | 50 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | 54 | 50 | 57 | 44 | 21 | 24 | 38 | 19 | 24 | 33 | 13 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | 1 | ||||||
| Operating Lease Liability Noncurrent | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | 19 | 13 | 16 | 8 | ||||||
| Liabilities | 73 | 67 | 86 | 58 | 37 | 41 | 107 | 60 | 59 | 77 | 59 | ||||||
| Common Stock Value | 15 | 15 | 14 | 14 | 14 | 14 | 13 | 11 | 11 | 11 | 10 | ||||||
| Additional Paid In Capital Common Stock | 1,488 | 1,457 | 1,427 | 1,397 | 1,376 | 1,357 | 1,298 | 829 | 822 | 807 | 591 | ||||||
Stockholders Equity | |||||||||||||||||
| Stockholders Equity | 631 | 665 | 683 | 728 | 778 | 777 | 758 | 379 | 387 | 412 | 288 | ||||||
| Retained Earnings Accumulated Deficit | -875 | -811 | -762 | -687 | -615 | -598 | -559 | -466 | -450 | -411 | -317 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 4 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liabilities And Stockholders Equity | 704 | 733 | 769 | 786 | 815 | 818 | 865 | 439 | 447 | 488 | 347 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 118 | 117 | 114 | 113 | 113 | 112 | 108 | 92 | 90 | 90 | 82 | ||||||
| Shares Outstanding | 118 | 117 | 114 | 113 | 113 | 112 | 108 | 92 | 90 | 90 | 82 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNewAmsterdam Pharma Co N.V. (NAMS) — SEC Financial Statements & Analysis
NewAmsterdam Pharma Co N.V. (NAMS) is a pharmaceutical preparations company, incorporated in P7. NewAmsterdam Pharma Co N.V. trades on Nasdaq as: NAMS, NAMSW. NewAmsterdam Pharma Co N.V. (NAMS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, NewAmsterdam Pharma Co N.V. carries a market cap of $4.18B, a P/E ratio of -16.11x, a P/B ratio of 6.62x, a P/S ratio of 587.14x, an enterprise value of $3.76B, and an EV/EBITDA multiple of -15.39x. On profitability, it posts an operating margin of -3432.20%, a net margin of -3644.21%, a Return on Equity (ROE) of -36.81%, a Return on Assets (ROA) of -34.16%, and a Return on Invested Capital (ROIC) of -115.47%. Per share, it reports EPS of $-2.10, diluted EPS of $-2.10, free cash flow per share of $-1.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -88.87% year-over-year, net income growth of 56.60% year-over-year, and EPS growth of 50.49% year-over-year. On the balance sheet, it maintains a current ratio of 9.03x, a quick ratio of 8.70x, working capital of $586.23M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.1, free cash flow of $-143.72M (TTM), and net debt of $-424.15M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.18B
- P/E TTM
- -16.11x
- EPS TTM
- $-2.10
- P/B TTM
- 6.62x
- ROE TTM
- -36.81%
- ROA TTM
- -34.16%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-143.72M
- Net Revenue TTM Growth 1Y
- -88.87%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NewAmsterdam Pharma Co N.V. in?
NewAmsterdam Pharma Co N.V. (NAMS) operates in the Pharmaceutical Preparations industry.
What exchange does NAMS trade on?
NewAmsterdam Pharma Co N.V. (NAMS) trades on the Nasdaq.
Where is NewAmsterdam Pharma Co N.V. incorporated?
NewAmsterdam Pharma Co N.V. is incorporated in Netherlands.
When was NewAmsterdam Pharma Co N.V. (NAMS)'s most recent SEC filing?
NewAmsterdam Pharma Co N.V. (NAMS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is NAMS's market cap?
NewAmsterdam Pharma Co N.V. (NAMS) has a market capitalization of $4.18B as of 2026-06-30.
What is NAMS's EPS (earnings per share)?
NewAmsterdam Pharma Co N.V. (NAMS)'s trailing twelve month EPS is $-2.10 as of 2026-06-30.
What is NAMS's ROE (return on equity)?
NewAmsterdam Pharma Co N.V. (NAMS)'s trailing twelve month Return on Equity (ROE) is -36.81% as of 2026-06-30.
What is NAMS's ROA (return on assets)?
NewAmsterdam Pharma Co N.V. (NAMS)'s trailing twelve month Return on Assets (ROA) is -34.16% as of 2026-06-30.
What is NAMS's ROIC (return on invested capital)?
NewAmsterdam Pharma Co N.V. (NAMS)'s trailing twelve month Return on Invested Capital (ROIC) is -115.47% as of 2026-06-30.
What is NAMS's EV/EBITDA?
NewAmsterdam Pharma Co N.V. (NAMS)'s trailing twelve month EV/EBITDA is -15.39x as of 2026-06-30.